GoAI
Get started
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.83

−$0.02 · -0.52%

Aug 21, 4:00 PM ET

Pre-market

$3.71

−$0.12 · -3.13%

Aug 24, 6:52 AM ET

FULC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

34

Expensive

Momentum

19

Strong Down

Sentiment

35

Bearish

Risk resilience

14

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Alexander C. Sapir
Listed since
Jul 18, 2019
Employees
9

Market position

Day range

Current $3.83

52-week range

Current $3.83

Open
$3.85
Previous close
$3.85
Volume
1.51M
0.69× average
Average volume
2.18M
Average daily volume
Market cap
292.22M USD
Beta
3
Market reference 1
50-day average
$3.6936
+3.69% above average
200-day average
$7.5485
-49.26% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.17×
P/B (TTM)
0.94×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends417%-1169%-2755%-4342%Gross margin, FY2021: -263.73%Gross margin, FY2022: -1110.69%Gross margin, FY2023: -2459.75%Gross margin, FY2024: 20.77%Operating margin, FY2021: -422.97%Operating margin, FY2022: -1774.85%Operating margin, FY2023: -3945.24%Operating margin, FY2024: -27.37%Net margin, FY2021: -421.89%Net margin, FY2022: -1732.43%Net margin, FY2023: -3470.05%Net margin, FY2024: -12.16%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -263.73%. Gross margin FY2022 -1110.69%. Gross margin FY2023 -2459.75%. Gross margin FY2024 20.77%. Operating margin FY2021 -422.97%. Operating margin FY2022 -1774.85%. Operating margin FY2023 -3945.24%. Operating margin FY2024 -27.37%. Net margin FY2021 -421.89%. Net margin FY2022 -1732.43%. Net margin FY2023 -3470.05%. Net margin FY2024 -12.16%.

Income trends

Revenue

80M USD+2752.05%

Operating income

−84.77M USD-287.13%

Net income

−74.88M USD-669.97%
Income trends across reported periods99.26M USD22.23M USD−54.79M USD−131.82M USDRevenue, FY2021: 19.16M USDRevenue, FY2022: 6.34M USDRevenue, FY2023: 2.81M USDRevenue, FY2024: 80M USDOperating income, FY2021: −81.05M USDOperating income, FY2022: −112.56M USDOperating income, FY2023: −110.66M USDOperating income, FY2024: −21.9M USDOperating income, FY2025: −84.77M USDNet income, FY2021: −80.85M USDNet income, FY2022: −109.87M USDNet income, FY2023: −97.34M USDNet income, FY2024: −9.73M USDNet income, FY2025: −74.88M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 19.16M USD. Revenue FY2022 6.34M USD. Revenue FY2023 2.81M USD. Revenue FY2024 80M USD. Operating income FY2021 −81.05M USD. Operating income FY2022 −112.56M USD. Operating income FY2023 −110.66M USD. Operating income FY2024 −21.9M USD. Operating income FY2025 −84.77M USD. Net income FY2021 −80.85M USD. Net income FY2022 −109.87M USD. Net income FY2023 −97.34M USD. Net income FY2024 −9.73M USD. Net income FY2025 −74.88M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—80M USD2.81M USD6.34M USD19.16M USD
Cost of goods sold1.39M USD63.39M USD71.8M USD76.78M USD69.7M USD
Gross profit−1.39M USD16.61M USD−69M USD−70.44M USD−50.54M USD
Research and development56.1M USD63.39M USD71.8M USD76.78M USD69.7M USD
Selling, general, and administrative28.67M USD36.45M USD41.67M USD41.69M USD30.52M USD
Operating expenses83.38M USD38.51M USD41.67M USD42.12M USD30.52M USD
Interest income————207K USD
Depreciation and amortization1.39M USD1.59M USD2.17M USD2.41M USD2.52M USD
Operating income−84.77M USD−21.9M USD−110.66M USD−112.56M USD−81.05M USD
Net income−74.88M USD−9.73M USD−97.34M USD−109.87M USD−80.85M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

17 ratings
Strong buy00%
Buy741%
Hold741%
Sell318%
Strong sell00%

FULC news

gurufocus.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire

Read source
globenewswire.com

Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Read source
gurufocus.com

Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick and Foti, LLC (“KSF”) are investigating the proposed merger of

Read source
businesswire.com

Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Fulcrum Therapeutics, Inc.…

Read source
newsfilecorp.com

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm to Learn About Their Legal Rights

New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:…

Read source
defenseworld.net

Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal

Fulcrum Therapeutics (NASDAQ: FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter…

Read source

FULC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding FULC

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.43M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
5.89M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
3.79M
Weight
0.68%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.17M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.98M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.85M
Weight
0.03%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.61M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.19M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research FULC

research.disclaimer